STOCK TITAN

Nexalin Technology, Inc. - NXL STOCK NEWS

Welcome to our dedicated page for Nexalin Technology news (Ticker: NXL), a resource for investors and traders seeking the latest updates and insights on Nexalin Technology stock.

Nexalin Technology, Inc. (NASDAQ: NXL) is a pioneering company in the field of neurostimulation, offering non-invasive and drug-free therapies for individuals suffering from anxiety, depression, and insomnia. The company has developed a patented device that uses transcranial electrical stimulation (tES), producing a unique waveform designed to stimulate brain activity and normalize neurochemical levels. This treatment aims to provide lasting relief from mental health conditions without the adverse side effects typically associated with drugs or psychotherapy.

One of the core products from Nexalin is the Gen-1 device, classified as a Class II medical device by the U.S. Food and Drug Administration (FDA). This cranial electrotherapy stimulation (CES) device emits a waveform at 4 milliamps during treatments and has been shown to increase beta-endorphins significantly during clinical trials.

Nexalin is also advancing the development of its Gen-2 and Gen-3 HALO™ Clarity devices, which aim to offer deeper brain penetration and enhanced patient response without side effects. The company's Gen-2 device was recently approved by the National Medical Products Administration (NMPA) in China for treating insomnia and depression and is distributed in the Asia Pacific region through a joint venture with Wider Come Limited.

Recent achievements include a collaborative study involving the U.S. Department of Veterans Affairs and UC San Diego, which demonstrated a significant decrease in post-concussion syndrome (PCS) and PTSD symptoms in veteran patients using the Gen-2 device. Moreover, the company continues to gather clinical data supporting its neurostimulation technology and is making progress in advancing its new Gen-3 HALO™ Clarity Virtual Clinic model.

Nexalin is committed to addressing the global mental health crisis through innovative solutions. The company's non-invasive devices are developed to be undetectable to the human body, ensuring a comfortable treatment experience. With ongoing research and development, Nexalin aims to extend the reach of its therapies to benefit more people worldwide.

Rhea-AI Summary

Nexalin Technology announced that the FDA has provided feedback and reached consensus on the design for clinical studies of its Gen-3 HALO Clarity™ headset. These studies, focusing on anxiety and insomnia, are set to commence in Q3 2024. Each study will involve 75 patients receiving active treatment and 75 receiving sham treatment. The HALO device uses Deep Intracranial Frequency Stimulation (DIFS™) to potentially offer an effective alternative to pharmacological treatments. Following the studies, Nexalin plans to submit a De Novo request to the FDA, seeking a new marketing pathway for the device.

The production of over 500 units of the HALO headset has started to support these studies. Nexalin aims to manage the patient-physician relationship through a virtual clinic model, allowing at-home use with remote monitoring by a physician. CEO Mark White sees this as a significant step towards revolutionizing mental health treatment standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary

Nexalin Technology announced that its new division, Nexalin America, has joined the National Traumatic Brain Injury (TBI) Registry Coalition. This Coalition comprises private sector and non-profit organizations dedicated to advancing research, raising awareness, and supporting clinical trials for TBI, affecting millions annually. Members include the NFL Players Association, Spaulding Rehabilitation at Mass General, United States Brain Injury Alliance, Abbott, and American Academy of Neurology. Nexalin America will leverage its neurostimulation technology expertise to contribute to developing a national TBI registry. CEO Mark White highlighted this partnership as a significant step towards combating brain injuries through advanced technology and collaborative research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Nexalin Technology, Inc. is hosting an exclusive live investor webinar on May 23, 2024, featuring CEO Mark White discussing the company's clinical data on its deep brain stimulation device and new clinic model. Investors can register for the event and submit questions online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
none
Rhea-AI Summary
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has regained compliance with Nasdaq's minimum bid price requirement under Nasdaq Rule 5550(a)(2). CEO Mark White expresses commitment to revolutionizing mental health treatment through neurostimulation technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
-
Rhea-AI Summary
Nexalin Technology, Inc. (NXL) reports on growing clinical data supporting its neurostimulation technology and progress advancing its new Gen-3 HALO™ Clarity Virtual Clinic model. The company's CEO, Mark White, highlights positive clinical results, the introduction of HALO™ Clarity & Virtual Clinic, targeting the U.S. Government market, global market expansion, strengthening IP portfolio, and a bright future for Nexalin and mental health care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
none
-
Rhea-AI Summary
Nexalin Technology, Inc. completes successful testing for its new Gen-3 HALO™ Clarity neurostimulation device, ramping up manufacturing for upcoming clinical trials. The device offers remote treatment capabilities, potentially revolutionizing mental health disorder treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.72%
Tags
none
Rhea-AI Summary
Nexalin Technology, Inc. receives a new method of use patent for their non-invasive deep brain stimulation device, enabling treatment for anxiety, depression, and insomnia from the comfort of patients' homes. The patent covers the technology utilized in their Gen-3 HALO Clarity™ system, extending through 2040. CEO Mark White highlights the significance of the patent in enhancing the company's strategy and clinical data supporting the device's benefits. The Gen-3 system represents a state-of-the-art development in Nexalin's technology, offering painless neural stimulation for mental health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.42%
Tags
none
-
Rhea-AI Summary
Nexalin Technology, Inc. appoints former Acting General Counsel to the Department of Veterans Affairs, William A. Hudson, Jr., to its Military & Government Advisory Board. Hudson's extensive experience in military and government law will aid Nexalin in advancing its non-invasive, deep-brain stimulation devices for mental health conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
51.05%
Tags
management
-
Rhea-AI Summary
Nexalin Technology, Inc. announced positive results from a clinical study on its Gen-2 tACS device for treating pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study showed a significant decrease in PCS and PTSD symptoms compared to the control group. The company's strategy aims to provide a non-medication treatment option for mTBI without side effects, supported by VA and UCSD collaboration. The study was a randomized, double-blind trial with promising outcomes, reinforcing Nexalin's commitment to improving mental healthcare outcomes for patients with mTBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
79.49%
Tags
Rhea-AI Summary
Nexalin Technology, Inc. presented its Gen-3 Halo Clarity device at the 'State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment' hosted by USAMRDC and BARDA. The device aims to treat TBI, PTSD, and other conditions non-invasively. The company received positive feedback from leading experts and government officials, indicating a growing interest in non-drug therapeutic options for TBI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.17%
Tags
none

FAQ

What is the current stock price of Nexalin Technology (NXL)?

The current stock price of Nexalin Technology (NXL) is $2.63 as of December 20, 2024.

What is the market cap of Nexalin Technology (NXL)?

The market cap of Nexalin Technology (NXL) is approximately 37.3M.

What does Nexalin Technology, Inc. do?

Nexalin Technology, Inc. develops non-invasive, drug-free neurostimulation devices to treat anxiety, depression, and insomnia.

What is the core product of Nexalin Technology?

Nexalin's core product is the Gen-1 device, a cranial electrotherapy stimulation (CES) device that emits a unique waveform to normalize neurochemical levels.

Is the Nexalin device FDA approved?

Yes, Nexalin's Gen-1 device is classified as a Class II medical device by the FDA.

What recent achievements has Nexalin Technology made?

Nexalin recently announced a successful clinical study involving veteran patients with PCS and PTSD and obtained approval for its Gen-2 device in China.

How does Nexalin’s technology work?

Nexalin's technology uses transcranial electrical stimulation (tES) to stimulate brain activity and adjust neurochemical levels without drugs or psychotherapy.

What makes Nexalin's therapy unique?

Nexalin's therapy is non-invasive, drug-free, and designed to be undetectable to the human body, providing lasting relief without side effects.

Where is Nexalin's Gen-2 device approved for use?

The Gen-2 device has been approved by the National Medical Products Administration (NMPA) in China for treating insomnia and depression.

What ongoing projects is Nexalin Technology involved in?

Nexalin is currently gathering clinical data to support its technology and advancing its Gen-3 HALO™ Clarity Virtual Clinic model.

Who are Nexalin’s partners in distributing their devices?

Nexalin's devices are distributed in the Asia Pacific region through a joint venture with Wider Come Limited.

How can I get more information about Nexalin Technology's latest developments?

You can visit Nexalin's official website or contact Crescendo Communications, LLC for the latest updates.

Nexalin Technology, Inc.

Nasdaq:NXL

NXL Rankings

NXL Stock Data

37.33M
10.40M
23.3%
2.41%
0.88%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States of America
HOUSTON